Inventaire - 友達とコミュニティはあなたのベストな図書館です - Inventaire

A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

著者

Keith Flaherty

Benjamin Izar

F Stephen Hodi

Reinhard Dummer

この作品が含まれる作品: Cancer Medicine

出版日: 2017-07-18

言語: 英語

main subject: metastatic melanoma

Cites articles 36

Date

タイトル

著者

2016

Cancer statistics, 2016
2015

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

F Stephen Hodi, Elizabeth I Buchbinder
2015-09-25

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Bernard Escudier, Frede Donskov, John Wagstaff, Giuseppe Procopio, Alain Ravaud, Howard Gurney, Robert Motzer, Toni K Choueiri
2015-06-01

Genomic Classification of Cutaneous Melanoma

Alexander J. Lazar
2015-04-20

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2015-06-25

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert, Adil Daud, Christian U Blank
2015-08-03

Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma

Brent A Appleton
2014-09-29

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

Caroline Robert, ジャン＝ジャック・グロブ, Dirk Schadendorf, Keith Flaherty, Daniil Stroyakovskiy, Ana Arance, Virginia Ferraresi, Evgeny V Levchenko, Igor N. Bondarenko, Jochen Utikal, ジョージナ・V・ロング, Filippo de Braud, Antoni Ribas, Axel Hauschild
2013-06-02

Nivolumab plus ipilimumab in advanced melanoma

Mario Sznol, Jedd D Wolchok
2013-07-11

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Bartosz Chmielowski, Antoni Ribas, Caroline Robert, Richard W. Joseph, Anthony M Joshua, Adil Daud, Richard F. Kefford, Jedd D Wolchok, F Stephen Hodi, Roxana S. Dronca, Tara C Gangadhar
2013-10-11

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma
2012-12-17

Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma

Richard F. Kefford, Keith Flaherty
2012-07-20

A landscape of driver mutations in melanoma

エリック・ランダー, Gad Getz, Kristian Cibulskis, Wendy Winckler, Daniel Auclair, Gordon Saksena, Eran Hodis, Nicolas Stransky, Douglas Voet, Kristin Ardlie, Elizabeth Nickerson, Lynda Chin, Jean-Philippe Theurillat, Marcin Imielinski, Dirk Schadendorf, Jennifer Wargo, Donald Morton, John E. Ladbury, Gregory Kryukov, Katherine Stemke-Hale, Stefan T Arold, Stephan N. Wagner, Matthew Meyerson, Stacey Gabriel, Levi A Garraway, Andrey Sivachenko, Alex H Ramos
2012-06-04

Improved survival with MEK inhibition in BRAF-mutated melanoma

Claus Garbe, Mohammed Milhem, Piotr Rutkowski, Jochen Utikal, Jürgen C Becker, Reinhard Dummer
2012-02-23

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Bartosz Chmielowski, Antoni Ribas, Igor Puzanov, Grant McArthur, Richard F. Kefford, Keith Flaherty
2012-02-20

RAF265 inhibits the growth of advanced human melanoma tumors

Ann Richmond, Kelli L. Boyd
2012-03-26

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

Grant McArthur, Rodney J. Hicks, Keith Flaherty, Antoni Ribas
2012-11

600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors
2011-11-28

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma

Daniel S Chen
2011-11-04

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Andrey Kaprin, Dror Michaelson, Robert Motzer, Cezary Szczylik
2011-06-30

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Dirk Schadendorf, Antoni Ribas, Paul Lorigan, Claus Garbe, Axel Hauschild, Reinhard Dummer, Michele Maio, Alexander Eggermont, Caroline Robert, Grant McArthur, Keith Flaherty, Paolo Antonio Ascierto, James Larkin, John B A G Haanen, David Hogg, Alessandro Testori, Jeffrey A Sosman, Celeste Lebbe, Thomas Jouary
2011-10-05

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

Olivier Rixe
2011-01-22

A novel cross-talk between endothelin-1 and cyclic AMP signaling pathways in the regulation of GLUT1 transcription in 3T3-L1 adipocytes
2010-09-30

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Joseph Schlessinger, Antoni Ribas, Igor Puzanov, Grant McArthur, Katherine L Nathanson, Rafe Shellooe, Gideon Bollag, Gaston Habets, Keith Flaherty, Chao Zhang
2010-08-26

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Antoni Ribas, Igor Puzanov, Grant McArthur, Keith Flaherty
2010-08-19

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Dirk Schadendorf, Paul Lorigan, Christian H. Ottensmeier, Caroline Robert, Jedd D Wolchok, F Stephen Hodi
2010-03-18

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
2009-01-01

Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation

ルイス・カントレー, Lynda Chin
2008-08-01

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Keith Flaherty, David Tuveson
2008-05-01

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

F Stephen Hodi
2008-06-01

Critical aspects of the Bayesian approach to phase I cancer trials.

Beat Neuenschwander
2006

Cancer statistics, 2006

記事 - wd:Q41311583

Welcome to Inventaire

友達やコミュニティの図書館

もっと調べる

you are offline